AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · IEX Real-Time Price · USD
3.780
-0.060 (-1.56%)
At close: Apr 30, 2024, 4:00 PM
3.810
+0.030 (0.79%)
After-hours: Apr 30, 2024, 7:10 PM EDT
AbCellera Biologics Revenue
In the year 2023, AbCellera Biologics had annual revenue of $38.03M, a decrease of -92.17%. Revenue in the quarter ending December 31, 2023 was $9.18M, a -57.40% decrease year-over-year.
Revenue (ttm)
$38.03M
Revenue Growth
-92.17%
P/S Ratio
29.10
Revenue / Employee
$64,889
Employees
586
Market Cap
1.11B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
Dec 31, 2019 | 11.61M | 2.78M | 31.49% |
Dec 31, 2018 | 8.83M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 1.82B |
AtriCure | 399.25M |
Maravai LifeSciences Holdings | 288.95M |
MannKind | 198.96M |
Mirum Pharmaceuticals | 186.37M |
Prothena Corporation | 91.37M |
Vir Biotechnology | 86.18M |
Immatics | 60.00M |
ABCL News
- 22 days ago - AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 - Business Wire
- 27 days ago - AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 6 weeks ago - AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 - Business Wire
- 7 weeks ago - AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions - Business Wire
- 2 months ago - AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 - Business Wire
- 2 months ago - AbCellera Announces Resignation of Board Member - Business Wire
- 2 months ago - AbCellera to Present at Upcoming Investor Conferences in March - Business Wire
- 2 months ago - AbCellera Reports Full Year 2023 Business Results - Business Wire